Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature

This literature review (2017) of randomized, placebo-controlled trials explores the effects of ketamine in treatment-resistant depression (TRD) and bipolar depression (BD). Ketamine reduced symptoms in both and is a promising compound for those who have found other treatments lacking.

Abstract of Ketamine for the treatment of major depressive disorder and bipolar depression

Introduction: Over the past decade, ketamine has been studied for major depressive disorder and bipolar depression. Ketamine is believed to exert its antidepressant properties through N-methyl-D-aspartate receptor antagonism.

Methods: Study authors completed a literature review of seven randomized controlled trials of ketamine usage in major depressive disorder and bipolar depression.

Results: Ketamine demonstrated a statistically significant improvement over placebo or midazolam in major depressive disorder. Ketamine also exhibited a statistically significant improvement over placebo in bipolar depression.

Discussion: Ketamine has shown promise in quickly reducing symptoms in patients with treatment resistant depression and bipolar depression. Using ketamine may be helpful for patients that have exhausted other therapeutic options.

Authors: Sarah E. Grady, Travis A. Marsh, Allison Tenhouse & Kelsey Klein

Summary of Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature

Introduction

Ketamine is used for anaesthesia, analgesia, tachycardia, increased blood pressure, impaired memory and cognitive function, and visual changes in a dose-dependent manner. It is also used for the treatment of postoperative, chronic cancer, and neuropathic pain as well as procedural sedation in the emergency department.

Ketamine is given intravenously or intramuscularly for anaesthesia but can also be given orally, epidurally, intrathecally, and intranasally for pain management. It is metabolized to dehydronorketamine, norketamine, and hydroxynorketamine.

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature

https://doi.org/10.9740/mhc.2017.01.016

Open Access | Google Scholar | Backup | 🕊

Cite this paper (APA)

Grady, S. E., Marsh, T. A., Tenhouse, A., & Klein, K. (2017). Ketamine for the treatment of major depressive disorder and bipolar depression: a review of the literature. Mental Health Clinician7(1), 16-23.

Study details

Compounds studied
Ketamine

Topics studied
Bipolar Disorder Treatment-Resistant Depression Depression

Study characteristics
Literature Review

PDF of Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature